StockPriceToday
ACADIA Pharmaceuticals Inc. (ACAD)
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. specializes in developing and commercializing innovative medicines for central nervous system disorders, with a particular focus on rare and underserved neurological and neuropsychiatric conditions. The company's established commercial presence makes ACAD stock price sensitive to sales performance and pipeline development progress.
The company's lead product, NUPLAZID, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, representing a significant breakthrough in addressing previously underserved patient populations. ACAD's commercial success with NUPLAZID provides steady revenue streams that support ACAD stock price stability and fund continued research and development activities.
ACADIA's research pipeline includes programs targeting additional central nervous system disorders, including Alzheimer's disease psychosis, major depressive disorder, and other neurological conditions. The company's expertise in CNS drug development and regulatory pathways positions it well for future product launches that could drive ACAD stock price appreciation.
The company's focus on rare neurological conditions creates opportunities for premium pricing and market exclusivity, while its established commercial infrastructure enables efficient product launches. ACAD stock price reflects both the stability of its current commercial products and the potential upside from successful development of additional CNS therapies.
ACAD Stock 12 Month Chart
Latest News for ACAD
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Key Stats for Acadia Pharmaceuticals StockToday’s Performance: -19%52-Week Range: $20 to $31Valuation Model Target Price: $34Implied Upside: 54%What Happened?Acadia Pharmaceuticals stock (NASDAQ: ACAD ...
ACADIA Pharmaceuticals has reported recent quarterly results while advancing its neuroscience pipeline, keeping the focus on revenue trends for Nuplazid and growth from new products. This article ...
Other Popular Stocks
Henry Schein Inc. (HSIC) is a healthcare distribution company providing products, services, and technology solutions to dental, medical, and veterinary practitioners worldwide.
Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Monarch Casino & Resort Inc. (MCRI) is a gaming and hospitality company operating casino resorts with hotels, dining, and entertainment facilities in Nevada and...